Gene Therapy Market Segmentation:
Type Segment Analysis
Gene silencing segment in the gene therapy market is estimated to grow substantially through 2035. The segment growth can be credited to the presence of several gene therapy products that use a method of gene silencing. Silencing genes has also been shown to be a useful strategy, particularly against neurological disorders like neuromuscular illnesses.
The effectiveness and specificity of gene silencing techniques have been greatly improved by ongoing developments in gene editing technologies, including CRISPR–Cas9, RNA interference (RNAi), and antisense oligonucleotides, which often reduce a gene’s expression by at least 70% without completely eliminating it.
Therapeutic Area Segment Analysis
Neurology segment in the gene therapy market is estimated to register lucrative growth till 2035. The segment is growing due to the technological advancements in gene therapy. Highly specific viral vector designs, plasmid transfection, nanoparticles, polymer–mediated gene delivery, engineered microRNA, and in vivo clustered regulatory interspaced short palindromic repeats (CRISPR)–based therapeutics have been the focus of recent technological advancements for improved gene sequence delivery.
Highly common neurological and neurodevelopmental disorders, such as Parkinson's disease, Alzheimer's disease, and autism spectrum disorder, can be effectively treated with these cutting–edge techniques. According to Alzheimer’s Disease International Organization, in 2020, there were about 55 million dementia patients worldwide. By 2050, there will be 139 million people on the planet, having nearly doubled every 20 years to 78 million in 2030. Therefore, the growing cases of such diseases are propelling the growth of the segment.
Route of Administration Segment Analysis
By the end of 2035, intravenous segment is estimated to capture gene therapy market share of around 60%. The primary driver of the segment's dominance is the substantial pipeline of IV candidates and the high number of approved medications. The least complex and intrusive technique for cardiac gene transfer that is currently available is intravenous injection. Injection into the tail vein of rodents successfully expresses the cardiac gene. Throughout the projected period, this segment is likewise anticipated to become the most lucrative.
Our in–depth analysis of the market includes the following segments:
|
Type |
|
|
Vector |
|
|
Therapeutic Area |
|
|
Delivery Method |
|
|
Route of Administration |
|
